These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34895653)

  • 1. Development challenges of high concentration monoclonal antibody formulations.
    Kollár É; Balázs B; Tari T; Siró I
    Drug Discov Today Technol; 2020 Dec; 37():31-40. PubMed ID: 34895653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies.
    Carrara SC; Ulitzka M; Grzeschik J; Kornmann H; Hock B; Kolmar H
    Int J Pharm; 2021 Feb; 594():120164. PubMed ID: 33309833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges for the pharmaceutical technical development of protein coformulations.
    Mueller C; Altenburger U; Mohl S
    J Pharm Pharmacol; 2018 May; 70(5):666-674. PubMed ID: 28470967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and Administration of Biological Medicinal Products".
    Krämer I; Thiesen J; Astier A
    Pharm Res; 2020 Aug; 37(8):159. PubMed ID: 32743712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical Stability of Monoclonal Antibodies: A Review.
    Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V
    J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filling of High-Concentration Monoclonal Antibody Formulations into Pre-filled Syringes: Investigating Formulation-Nozzle Interactions To Minimize Nozzle Clogging.
    Shieu W; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(3):417-26. PubMed ID: 26048747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise.
    Khan SR; Kona R; Faustino PJ; Gupta A; Taylor JS; Porter DA; Khan M
    J Pharm Sci; 2014 May; 103(5):1331-6. PubMed ID: 24623105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
    Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
    J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for Cell-Based Medicinal Products From a Pharmaceutical Product Perspective.
    Jere D; Sediq AS; Huwyler J; Vollrath I; Kardorff M; Mahler HC
    J Pharm Sci; 2021 May; 110(5):1900-1908. PubMed ID: 33307042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of syringes and vials for delivery of biologics: current challenges and innovative solutions.
    Yoneda S; Torisu T; Uchiyama S
    Expert Opin Drug Deliv; 2021 Apr; 18(4):459-470. PubMed ID: 33217252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein aggregation and immunogenicity of biotherapeutics.
    Pham NB; Meng WS
    Int J Pharm; 2020 Jul; 585():119523. PubMed ID: 32531452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Tunable Resistive Pulse Sensing for the Quantification of Submicron Particles in Pharmaceutical Monoclonal Antibody Preparations.
    Stelzl A; Schneid S; Winter G
    J Pharm Sci; 2021 Nov; 110(11):3541-3545. PubMed ID: 34303672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-concentration protein formulations: How high is high?
    Garidel P; Kuhn AB; Schäfer LV; Karow-Zwick AR; Blech M
    Eur J Pharm Biopharm; 2017 Oct; 119():353-360. PubMed ID: 28690199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.